Active, not recruitingPHASE1, PHASE2NCT05395741

Regorafenib in Patients With Refractory Primary Bone Tumors

Studying Osteosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Mother and Child, Warsaw, Poland
Principal Investigator
Anna Raciborska, Prof., MD
the Institue of Mother and Child
Intervention
Regorafenib(drug)
Enrollment
30 target
Eligibility
9-21 years · All sexes
Timeline
20222026

Study locations (2)

Collaborators

Maria Sklodowska-Curie National Research Institute of Oncology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05395741 on ClinicalTrials.gov

Other trials for Osteosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Osteosarcoma

← Back to all trials